Axitinib

• Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence Pending
  2024-515825-27-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending
  2025-522431-34-00 Phase II 1 country Region Hovedstaden
• A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally… Pending
  2025-523524-53-00 Phase I/II 2 countries Pfizer Inc.
• CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting
  2024-517789-41-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medu… Recruiting
  2023-509585-38-00 Phase I/II 1 country Assistance Publique Hopitaux De Marseille
• Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting
  2024-511397-70-00 Phase II 2 countries Consorzio Oncotech
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 Phase III 10 countries Institut Gustave Roussy
• Immunological variables associated to ICI toxicity in cancer patients Recruiting
  2023-505360-11-00 Phase II 1 country Institut Jules Bordet
• Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma … Recruiting
  2024-513986-38-00 Phase II 1 country Centre Leon Berard
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has… Ended
  2024-514644-93-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
• Master Protocol for Avelumab Continuation Study. Ended
  2023-509466-38-00 Phase III 7 countries Pfizer Inc.
• A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumo… Ended
  2024-519176-95-00 Phase II 2 countries Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada…
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 Phase III 7 countries Merck Sharp & Dohme LLC

Showing 1–14 of 14 trials